This blog draws on findings from the, Global and China Synthetic Biology and Biomanufacturing Industry Development Whitepaper, published by Frost & Sullivan China.
Executive Summary
Synthetic biology and biomanufacturing are developing along different paths across major economies. The United States has established research and commercialization networks but faces regulatory gaps for emerging technologies. The European Union combines a strong green policy framework with strict risk controls, although lengthy approval processes can slow commercialization. The United Kingdom draws on its academic and technology-transfer strengths, while China continues to expand its research capabilities and industrial applications.
China’s next stage of development will depend on addressing constraints in process engineering, specialized equipment, market-access frameworks, interdisciplinary talent, and core software and hardware. Resolving these gaps will strengthen the connection between basic research, pilot testing, and large-scale production.
For providers, long-term growth will require technically differentiated applications, predictable regulatory pathways, access to pilot infrastructure, and closer coordination between digital tools and production equipment.
Key Takeaways
- Scale-up requires more than laboratory success: Pilot testing, specialized equipment, and reliable production processes are needed to move research toward commercial manufacturing.
- Technology and production must work together: Advances in biological design need to align with process development and manufacturing requirements.
- Industry approaches differ across major economies: The United States, China, the European Union, and the United Kingdom follow different policy, regulatory, and commercialization models.
- Providers need a clear path to production: High-barrier applications, regulatory certainty, pilot-scale access, and software-hardware integration should be considered early.
Synthetic biology is emerging as a major force in life sciences. Its applications now extend across biopharmaceuticals, advanced materials, consumer goods, agriculture, energy, and environmental protection. However, turning research breakthroughs into commercial products requires biomanufacturing capacity that can support mass production.
To bridge this gap, major economies are investing in research, pilot-scale platforms, and commercial demonstration projects. China is expanding its role through national planning, a broad industrial base, growing scientific output, and wider market applications.
Is your organization prepared to take synthetic biology research into industrial production?
What Is Meant by Biomanufacturing?
Biomanufacturing uses engineered biological systems and production processes to manufacture products such as active pharmaceutical ingredients, fine chemicals, nutritional components, advanced materials, and energy products. It provides the production pathway needed to translate synthetic biology research into industrial value.
5 Challenges Slowing Industrial-scale Biomanufacturing
Addressing the following constraints will help more synthetic biology projects progress toward production:
- Feedstock limitations: Food-based feedstocks compete with food and animal-feed supplies, while alternative feedstocks such as non-food biomass remain costly to collect and difficult to process consistently.
- Dependence on specialized technologies: Key equipment, tool enzymes, and chassis cells used as biological production hosts are controlled by a limited number of global companies, creating supply-chain risks.
- Gaps between research and production: Limited pilot-scale capacity and weak coordination between industry and research institutions leave many findings at the laboratory stage.
- Inconsistent governance: Differences in ethical, safety, and risk-management standards complicate cross-border research, technology collaboration, and trade.
- Interdisciplinary talent shortages: Training programs do not always provide the combined expertise in biology, engineering, and technology transfer required by the industry.
Disruptive Technologies Enabling Biological Design and Process Development
The following technologies support the design and development of biological systems:
- Gene sequencing: Determines the order of deoxyribonucleic acid (DNA) bases for genome analysis. Improvements in read length, throughput, accuracy, and cost are broadening its applications.
- Gene editing: Enables precise changes at specific locations in a genome. Clustered Regularly Interspaced Short Palindromic Repeats and CRISPR-associated proteins (CRISPR/Cas) are widely used because the system is programmable, relatively easy to apply, and cost-effective.
- Gene synthesis: Produces double-stranded DNA for artificial gene circuits and genetic-part libraries. Current advances focus on longer fragments, higher throughput, faster synthesis, and lower costs.
- Bioinformatics and Artificial Intelligence (AI): Process large biological datasets and identify patterns within them. This supports data-driven iteration across the Design-Build-Test-Learn (DBTL) workflow.
- Metabolic engineering: Modifies metabolic and regulatory networks in microbes and plants. These changes improve existing production pathways or introduce new routes for active pharmaceutical ingredients, fine chemicals, and nutritional components.
- Multi-omics and systems biology: Examine multiple layers of biological data to provide a more complete view of biological systems. This improves the precision of chassis construction and synthetic-pathway design.
Regional Approaches to Synthetic Biology and Biomanufacturing
Synthetic biology and biomanufacturing are developing through distinct regional models shaped by differences in regulation, research infrastructure, industrial capacity, investment, and technology-transfer mechanisms.
United States
- Policy and regulation: The United States regulates products according to their characteristics and intended use. However, policy guidance and regulatory updates have not kept pace with AI-enabled design and cell-free platforms.
- Industry development: Massachusetts combines government support with academic research to build technical capacity. California draws on capital and entrepreneurship to support commercialization.
China
- Policy and regulation: National plans and multi-ministry policies have prioritized synthetic biology and biomanufacturing. However, gaps in standards, pilot validation, market access, and regulatory coordination continue to slow industrialization.
- Industry development: Shenzhen has developed research infrastructure and innovation platforms that support fundamental research, technology development, and early-stage project incubation.
European Union
- Policy and regulation: The European Union classifies products by end use and risk under common rules implemented at regional and national levels. Its policy approach also covers research investment, regulatory reform, market access, and talent development.
- Industry development: Paris Biofoundry focuses on automated DBTL workflows. Bio Base Europe Pilot Plant supports process development, pilot-scale production, and custom manufacturing.
United Kingdom
- Policy and regulation: The United Kingdom has established regulatory responsibilities across industrial safety and end-use sectors. However, complex policy design, implementation delays, and regional differences create practical challenges.
- Industry development: SynbiCITE connects government, industry, academia, and research to support technology transfer, international expansion, and commercialization.
Companies to Action: Advancing Synthetic Biology and Biomanufacturing
These companies address different industry requirements, including biological research, precision editing, and downstream process equipment:
- Ginkgo Bioworks uses its industrial platform to shorten research and development cycles and reduce innovation costs, supporting the move toward commercial-scale production.
- Beam Therapeutics applies precision gene editing to engineered cell therapies. Its technology focuses on reducing off-target effects and improving the safety of gene therapies.
- JewelBio develops equipment and integrated downstream process platforms for biopharmaceutical production. These platforms are designed to reduce development risks and make scale-up more predictable.
Business Implications: What This Means for Industry Providers
For providers, the central question is where to compete and how to establish a practical route to production. Four decisions should be made early:
- Prioritize applications with defensible economics and technical barriers: Assess synthesis complexity, substitution difficulty, production costs, and customer requirements before selecting a target market.
- Build regulatory requirements into development: Clarify product classification, safety assessment, environmental controls, and market-access requirements before committing significant resources.
- Use pilot testing as an investment checkpoint: Validate yield, stability, process controls, and product quality before expanding production capacity.
- Connect AI with manufacturing operations: Link AI-supported pathway design and strain engineering with process optimization, production monitoring, and quality control.
Future Outlook
Synthetic biology and biomanufacturing are moving toward closer coordination between biological design, process engineering, and industrial production. Pilot-platform networks, shared capacity, and unified industry standards will be important for connecting laboratory research, pilot testing, and large-scale manufacturing.
According to Frost & Sullivan, the next phase will also require closer coordination between AI for Science and AI for Industry. AI can support target prediction, pathway design, and strain engineering during research, while intelligent systems can assist pilot-scale operations, process control, and quality management during production.
Ready to Lead the Transformation?
- Schedule a Growth Strategy Dialog: Align your growth roadmap with Frost & Sullivan’s Visionary Growth Pipeline™ Dialog.
- Engage with Growth Experts: Co-design AI-enabled, data-driven operating models that scale industry-specific and commercial impact.
- Showcase Your Transformational Leadership: Position your organization as a transformation leader through Frost & Sullivan’s Transformational Growth Leadership platform.
- Join the Growth Council: Collaborate with industry leaders shaping the future of your ecosystem.
- Explore Best Practices Recognition: Be recognized for excellence in growth strategy, execution, and customer impact.
- Benchmark Your Industry Positioning on the Frost Radar™: Benchmark your growth performance and innovation strength against industry competitors.
- Tell Your Story: Accelerate awareness, engagement, and revenue growth through integrated brand and demand generation strategies.
Frequently Asked Questions (FAQs)
What is the difference between synthetic biology and biomanufacturing?
Synthetic biology designs or modifies biological systems using tools such as gene editing, gene synthesis, and metabolic engineering. Biomanufacturing uses cells, microorganisms, enzymes, and engineered production processes to manufacture products at scale. In simple terms, synthetic biology develops the biological design, while biomanufacturing turns that design into products.
What are some examples of biomanufacturing?
Examples of biomanufacturing include producing active pharmaceutical ingredients, fine chemicals, nutritional components, advanced materials, and energy products using microorganisms, cells, or enzymes. These biological systems can be engineered to convert feedstocks into useful products through controlled fermentation and other production processes.
Can you give me an example of synthetic biology?
One example of synthetic biology is engineering a microorganism to produce an active pharmaceutical ingredient. Researchers can modify the organism’s metabolic pathways so that it converts a selected feedstock into the required compound, which can then be tested, refined, and manufactured through a biomanufacturing process.
What is synthetic biology?
Synthetic biology is an engineering-based approach to designing and modifying biological systems. It uses technologies such as gene sequencing, gene editing, gene synthesis, metabolic engineering, bioinformatics, and artificial intelligence to build or improve biological functions for applications across healthcare, materials, agriculture, energy, and environmental protection.
Why is pilot-scale validation important in biomanufacturing?
Pilot-scale validation tests whether a biological process remains stable, efficient, and reproducible at a larger volume. It helps identify problems with yield, equipment, process controls, and product quality before a provider commits resources to commercial-scale manufacturing.
How is artificial intelligence used in synthetic biology and biomanufacturing?
Artificial intelligence supports target prediction, pathway design, strain engineering, and biological data analysis during research and development. In biomanufacturing, intelligent systems can also support process optimization, production monitoring, and quality control.
What are the main challenges in scaling biomanufacturing?
Scaling biomanufacturing can be constrained by feedstock availability, specialized equipment, limited pilot-scale capacity, process stability, regulatory requirements, and shortages of interdisciplinary talent. Successful scale-up requires coordination between biological design, process engineering, production systems, and quality controls.
